文献速递免疫规划

一种用于疫苗的高转基因表达与免疫原性新型DNA平台

A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity.
PubMed 文献 · Vaccine · 2021-11-10

研究开发了质粒载体pIDV-II,以pVax1为基础,通过替换启动子、poly-A信号、删除T7和AmpR启动子及倒置ORI-Neo/Kan盒,显著提高体外eGFP表达。在三种病毒抗原中,pIDV-II的转基因表达持续高于pVax1和pCAGGS对照。小鼠免疫后,pIDV-II诱导的体液和细胞免疫反应比pVax1强2倍或以上(ELISA和ELISPOT)。

要点

  • pIDV-II载体在体外显著提高eGFP和三种病毒抗原的转基因表达。
  • 小鼠免疫后,pIDV-II诱导的体液和细胞免疫反应比pVax1强2倍或以上。
  • pIDV-II为DNA疫苗和基因治疗提供额外选择。

核心结论

  • pIDV-II诱导稳健的转基因表达,并伴随针对目标转基因的细胞和体液免疫反应改善,优于pVax1。

研究设计与样本

  • 开发质粒载体pIDV-II,基于pVax1,包含鸡β-肌动蛋白启动子(CAG)、内含子、两个限制性酶切位点、转录后调控元件和转录终止信号。
  • 在细胞系中比较pIDV-II与pVax1或pCAGGS对照的三种病毒抗原表达水平。
  • 用表达各病毒抗原的pIDV-II或pVax1免疫小鼠,通过ELISA和ELISPOT检测体液和细胞反应。

主要发现

  • 修饰pVax1元件或降低eGFP表达水平或无影响,而替换启动子、poly-A信号、删除T7和AmpR启动子及倒置ORI-Neo/Kan盒显著增加体外eGFP表达。
  • 在三种病毒抗原中,pIDV-II的转基因表达持续高于pVax1和pCAGGS对照。
  • 小鼠免疫后,pIDV-II诱导的体液和细胞反应比pVax1强2倍或以上(ELISA和ELISPOT)。

临床怎么用

  • pIDV-II为动物和人类DNA疫苗接种及基因治疗提供额外替代选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of new, low-cost vaccines and effective gene therapies requires accurate delivery and high-level expression of candidate genes. We developed a plasmid vector, pIDV-II, that allows for both easy manipulation and high expression of exogenous genes in mammalian cells. This plasmid is based upon the pVax1 plasmid and shares a common structure with typical mammalian transcription units. It is composed of a chicken β-actin promoter (CAG), followed by an intron and flanked by two restriction sites, and also includes a post-transcriptional regulatory element, followed by a transcriptional termination signal. While the modification of pVax1 elements either decreased eGFP expression levels or had no effect at all, replacement of the promoter, the poly-A signal, deletion of the T7 and AmpR promoters, and inversion of the ORI-Neo/Kan cassette, significantly increased in vitro eGFP expression with the modified plasmid called pIDV-II. To further evaluate our vector, expression levels of three viral antigens were compared in cell lines transfected either with pVax1 or pCAGGS backbones as controls. Higher transgene expression was consistently observed with pIDV-II. The humoral and cellular responses generated in mice immunized with pIDV-II vs pVax1 expressing each viral antigen individually were superior by 2-fold or more as measured by ELISA and ELISPOT assays. Overall these results indicate that pIDV-II induces robust transgene expression, with concomitant improved cellular and humoral immune responses against the transgene of interest over pVax1. The new vector, pIDV-II, offers an additional alternative for DNA based vaccination and gene therapy for animal and human use.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Babuadze GG, Echanove J, Lamarre C, et al. A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity. Vaccine. 2021. PMID: 34774358. doi:10.1016/j.vaccine.2021.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。